Xenon Pharmaceuticals Inc. (NASDAQ:XENE) is scheduled to issue its quarterly earnings data after the market closes on Wednesday, November 1st. Analysts expect the company to announce earnings of ($0.08) per share for the quarter.

Xenon Pharmaceuticals (NASDAQ:XENE) last announced its quarterly earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($0.41) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.38) by ($0.03). Xenon Pharmaceuticals had a negative return on equity of 47.53% and a negative net margin of 3,489.63%. The company had revenue of $0.02 million for the quarter, compared to the consensus estimate of $0.38 million. On average, analysts expect Xenon Pharmaceuticals to post $-0.96 EPS for the current fiscal year and $-1.23 EPS for the next fiscal year.

Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE) opened at 3.10 on Wednesday. The company’s 50-day moving average price is $3.05 and its 200 day moving average price is $3.43. The company’s market cap is $55.79 million. Xenon Pharmaceuticals Inc. has a one year low of $2.25 and a one year high of $9.95.

COPYRIGHT VIOLATION NOTICE: “Xenon Pharmaceuticals Inc. (XENE) Set to Announce Quarterly Earnings on Wednesday” was reported by American Banking News and is owned by of American Banking News. If you are reading this piece on another publication, it was illegally copied and republished in violation of US & international trademark and copyright laws. The original version of this piece can be read at https://www.americanbankingnews.com/2017/10/25/xenon-pharmaceuticals-inc-xene-set-to-announce-quarterly-earnings-on-wednesday.html.

A number of brokerages have issued reports on XENE. Zacks Investment Research upgraded Xenon Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Thursday, October 5th. Jefferies Group LLC set a $5.00 price objective on Xenon Pharmaceuticals and gave the company a “buy” rating in a research note on Friday, August 4th. Finally, Canaccord Genuity reiterated a “buy” rating and set a $5.00 price objective on shares of Xenon Pharmaceuticals in a research note on Tuesday, June 27th.

In other Xenon Pharmaceuticals news, Director Mohammad Azab bought 10,000 shares of Xenon Pharmaceuticals stock in a transaction on Friday, September 22nd. The stock was acquired at an average price of $2.95 per share, with a total value of $29,500.00. Following the acquisition, the director now owns 21,210 shares in the company, valued at $62,569.50. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, major shareholder Bvf Partners L. P/Il bought 18,858 shares of Xenon Pharmaceuticals stock in a transaction on Tuesday, August 15th. The stock was acquired at an average cost of $2.41 per share, with a total value of $45,447.78. The disclosure for this purchase can be found here. In the last three months, insiders acquired 210,739 shares of company stock valued at $568,975. Corporate insiders own 9.40% of the company’s stock.

About Xenon Pharmaceuticals

Xenon Pharmaceuticals Inc is a Canada-based clinical-stage biopharmaceutical company. It is engaged in discovering and developing a pipeline of differentiated therapeutics for orphan indications. Its product pipeline includes: Glybera, TV-45070, GDC-0310, XEN901 (Nav1.6 inhibitor) and XEN1101. Glybera is used for the treatment of lipoprotein lipase deficiency (LPLD).

Earnings History for Xenon Pharmaceuticals (NASDAQ:XENE)

Receive News & Ratings for Xenon Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xenon Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.